About this data
What it is
An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
Who files it
The investor, within days of crossing 5%, and again whenever the stake changes materially.
How current
We collect new filings throughout the day on SEC business days.
Worth knowing
13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.

All of this comes from public filings.

Filings per day, last 30 days

0200400600800Oct 17 · 13D (activist): 0Oct 17 · 13G (passive): 0Oct 17Oct 18 · 13D (activist): 0Oct 18 · 13G (passive): 0Oct 19 · 13D (activist): 13Oct 19 · 13G (passive): 75Oct 20 · 13D (activist): 16Oct 20 · 13G (passive): 34Oct 21 · 13D (activist): 11Oct 21 · 13G (passive): 31Oct 21Oct 22 · 13D (activist): 16Oct 22 · 13G (passive): 48Oct 23 · 13D (activist): 13Oct 23 · 13G (passive): 24Oct 24 · 13D (activist): 0Oct 24 · 13G (passive): 0Oct 25 · 13D (activist): 0Oct 25 · 13G (passive): 0Oct 25Oct 26 · 13D (activist): 19Oct 26 · 13G (passive): 25Oct 27 · 13D (activist): 16Oct 27 · 13G (passive): 380Oct 28 · 13D (activist): 22Oct 28 · 13G (passive): 60Oct 29 · 13D (activist): 16Oct 29 · 13G (passive): 47Oct 29Oct 30 · 13D (activist): 16Oct 30 · 13G (passive): 343Oct 31 · 13D (activist): 0Oct 31 · 13G (passive): 0Nov 1 · 13D (activist): 0Nov 1 · 13G (passive): 0Nov 2 · 13D (activist): 20Nov 2 · 13G (passive): 36Nov 2Nov 3 · 13D (activist): 22Nov 3 · 13G (passive): 45Nov 4 · 13D (activist): 19Nov 4 · 13G (passive): 67Nov 5 · 13D (activist): 15Nov 5 · 13G (passive): 311Nov 6 · 13D (activist): 40Nov 6 · 13G (passive): 191Nov 6Nov 7 · 13D (activist): 0Nov 7 · 13G (passive): 0Nov 8 · 13D (activist): 0Nov 8 · 13G (passive): 0Nov 9 · 13D (activist): 40Nov 9 · 13G (passive): 140Nov 10 · 13D (activist): 27Nov 10 · 13G (passive): 289Nov 10Nov 11 · 13D (activist): 0Nov 11 · 13G (passive): 0Nov 12 · 13D (activist): 34Nov 12 · 13G (passive): 277Nov 13 · 13D (activist): 26Nov 13 · 13G (passive): 690Nov 14 · 13D (activist): 0Nov 14 · 13G (passive): 0Nov 14Nov 15 · 13D (activist): 0Nov 15 · 13G (passive): 0
0200400600800Oct 17 · 13D (activist): 0Oct 17 · 13G (passive): 0Oct 17Oct 18 · 13D (activist): 0Oct 18 · 13G (passive): 0Oct 19 · 13D (activist): 13Oct 19 · 13G (passive): 75Oct 20 · 13D (activist): 16Oct 20 · 13G (passive): 34Oct 21 · 13D (activist): 11Oct 21 · 13G (passive): 31Oct 21Oct 22 · 13D (activist): 16Oct 22 · 13G (passive): 48Oct 23 · 13D (activist): 13Oct 23 · 13G (passive): 24Oct 24 · 13D (activist): 0Oct 24 · 13G (passive): 0Oct 25 · 13D (activist): 0Oct 25 · 13G (passive): 0Oct 25Oct 26 · 13D (activist): 19Oct 26 · 13G (passive): 25Oct 27 · 13D (activist): 16Oct 27 · 13G (passive): 380Oct 28 · 13D (activist): 22Oct 28 · 13G (passive): 60Oct 29 · 13D (activist): 16Oct 29 · 13G (passive): 47Oct 29Oct 30 · 13D (activist): 16Oct 30 · 13G (passive): 343Oct 31 · 13D (activist): 0Oct 31 · 13G (passive): 0Nov 1 · 13D (activist): 0Nov 1 · 13G (passive): 0Nov 2 · 13D (activist): 20Nov 2 · 13G (passive): 36Nov 2Nov 3 · 13D (activist): 22Nov 3 · 13G (passive): 45Nov 4 · 13D (activist): 19Nov 4 · 13G (passive): 67Nov 5 · 13D (activist): 15Nov 5 · 13G (passive): 311Nov 6 · 13D (activist): 40Nov 6 · 13G (passive): 191Nov 6Nov 7 · 13D (activist): 0Nov 7 · 13G (passive): 0Nov 8 · 13D (activist): 0Nov 8 · 13G (passive): 0Nov 9 · 13D (activist): 40Nov 9 · 13G (passive): 140Nov 10 · 13D (activist): 27Nov 10 · 13G (passive): 289Nov 10Nov 11 · 13D (activist): 0Nov 11 · 13G (passive): 0Nov 12 · 13D (activist): 34Nov 12 · 13G (passive): 277Nov 13 · 13D (activist): 26Nov 13 · 13G (passive): 690Nov 14 · 13D (activist): 0Nov 14 · 13G (passive): 0Nov 14Nov 15 · 13D (activist): 0Nov 15 · 13G (passive): 0

13D (activist) 13G (passive)

Latest ownership filings

Reset

Showing: ticker VTVT

Latest ownership filings
FiledScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders.CompanyInvestorShares% of sharesFiling
Oct 8, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Israel A. Englander342,4818.7%SCHEDULE 13G/A ↗
Oct 8, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Millennium Group Management LLC342,4818.7%SCHEDULE 13G/A ↗
Oct 8, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Millennium Management LLC342,4818.7%SCHEDULE 13G/A ↗
Oct 8, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Integrated Core Strategies (US) LLC312,1387.9%SCHEDULE 13G/A ↗
Jul 29, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Israel A. Englander269,8746.9%SCHEDULE 13G/A ↗
Jul 29, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Millennium Group Management LLC269,8746.9%SCHEDULE 13G/A ↗
Jul 29, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Millennium Management LLC269,8746.9%SCHEDULE 13G/A ↗
Jul 29, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Integrated Core Strategies (US) LLC249,0276.3%SCHEDULE 13G/A ↗
Apr 16, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Israel A. Englander225,0735.7%SCHEDULE 13G/A ↗
Apr 16, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Millennium Group Management LLC225,0735.7%SCHEDULE 13G/A ↗
Apr 16, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Millennium Management LLC225,0735.7%SCHEDULE 13G/A ↗
Apr 16, 2026SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Integrated Core Strategies (US) LLC198,7485.0%SCHEDULE 13G/A ↗
Mar 27, 2026SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Israel A. Englander198,2375.0%SCHEDULE 13G ↗
Mar 27, 2026SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Millennium Group Management LLC198,2375.0%SCHEDULE 13G ↗
Mar 27, 2026SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Millennium Management LLC198,2375.0%SCHEDULE 13G ↗
Dec 9, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Srinivas Akkaraju403,9429.9%SCHEDULE 13D/A ↗
Dec 9, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara Opportunity Fund GP, LLC152,8933.8%SCHEDULE 13D/A ↗
Dec 9, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara Opportunity Fund, L.P.152,8933.8%SCHEDULE 13D/A ↗
Dec 9, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara BioCapital GP, LLC246,4846.2%SCHEDULE 13D/A ↗
Dec 9, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara BioCapital, L.P.246,4846.2%SCHEDULE 13D/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Raymond Debbane393,0989.4%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Ulys, L.L.C.47,1721.2%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Avicenna Life Sci Master GP LLC47,1721.2%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Avicenna Life Sci Master Fund LP47,1721.2%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Siren, L.L.C.345,9268.4%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Invus Global Management, LLC345,9268.4%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Invus Public Equities Advisors, LLC345,9268.4%SCHEDULE 13G/A ↗
Nov 12, 2025SCHEDULE 13G/A (amended)VTVT
vTv Therapeutics Inc.
Invus Public Equities, L.P.345,9268.4%SCHEDULE 13G/A ↗
Sep 25, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Srinivas Akkaraju343,2239.9%SCHEDULE 13D/A ↗
Sep 25, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara Opportunity Fund GP, LLC118,0733.5%SCHEDULE 13D/A ↗
Sep 25, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara Opportunity Fund, L.P.118,0733.5%SCHEDULE 13D/A ↗
Sep 25, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara BioCapital GP, LLC221,0846.5%SCHEDULE 13D/A ↗
Sep 25, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara BioCapital, L.P.221,0846.5%SCHEDULE 13D/A ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Raymond Debbane348,08310.0%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Ulys, L.L.C.41,7701.3%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Avicenna Life Sci Master GP LLC41,7701.3%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Avicenna Life Sci Master Fund LP41,7701.3%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Siren, L.L.C.306,3138.8%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Invus Global Management, LLC306,3138.8%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Invus Public Equities Advisors, LLC306,3138.8%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Invus Public Equities, L.P.306,3138.8%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Ortav Yehudai340,5369.9%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Trails Edge Biotechnology Master Fund, LP340,5369.9%SCHEDULE 13G ↗
Sep 8, 2025SCHEDULE 13GVTVT
vTv Therapeutics Inc.
Trails Edge Capital Partners, LP340,5369.9%SCHEDULE 13G ↗
Sep 3, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Srinivas Akkaraju343,2239.9%SCHEDULE 13D/A ↗
Sep 3, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara BioCapital GP, LLC339,1579.9%SCHEDULE 13D/A ↗
Sep 3, 2025SCHEDULE 13D/A (amended)VTVT
vTv Therapeutics Inc.
Samsara BioCapital, L.P.339,1579.9%SCHEDULE 13D/A ↗

47 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 8:06 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances